Vizia Diagnostics

What Vizia Diagnostics does

Vizia Diagnostics is a privately held, GI-focused surgical pathology laboratory headquartered at 11390 Old Roswell Road, Suite 100, Alpharetta, Georgia. The legal entity is Robert S Smith MD Inc, doing business as VIZIA Diagnostics LLC. Its core offering is gastrointestinal pathology diagnostic services delivered by GI-subspecialty-trained pathologists and histotechnicians, supported by a real-time electronic results interface integrated with provider EHR systems. Named and quoted customers include Heritage Medical Center (an ambulatory surgery center), a gastroenterology practice in Atlanta, a gastroenterologist in Athens, GA, and Doctors Specialists Gastroenterology; the firm also supports patient-facing billing and records services.

The lab's technology stack centers on PathAI's AISight Image Management System — adopted in October 2024 — which provides cloud-native case management, workload balancing, and image management with AI tool integration for whole-slide pathology images. Provider-side workflow runs through the proprietary PathView portal (24/7 real-time report access) and the giComply electronic requisition system, which is intended to replace paper requisitions, jar labels, and patient logs. In January 2025, Vizia began facilitating orders for Castle Biosciences' TissueCypher Barrett's Esophagus test, an AI-driven precision-medicine assay that produces a 5-year probability of progression to high-grade dysplasia or esophageal cancer.

Commercially, Vizia operates a transaction-fee pathology services model, billing healthcare providers and payors for diagnostic reads and operating provider billing through XIFIN and patient billing through Persona Pay. Its go-to-market is B2B enterprise field sales targeting gastroenterologists, GI practices, and ambulatory surgery centers, primarily across the Southeast US, supplemented by content marketing and patient/provider education channels. The lab carries CLIA, CAP, ISO CAP, and New York State Department of Health clinical laboratory accreditations and is led by CEO Gregg Costantino with Ed Cochrane serving as Commercial Director.

Name

Vizia Diagnostics

Legal name

Robert S Smith MD Inc

Website

https://viziadx.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Vizia Diagnostics is a privately held, GI-focused surgical pathology laboratory in Alpharetta, Georgia, that delivers gastrointestinal pathology diagnostic services to gastroenterologists, GI practices, and ambulatory surgery centers, augmented by PathAI-powered digital workflows and Castle Biosciences' TissueCypher risk-prediction testing.

Ownership category

akta.pro rank

Product category

Gastrointestinal Pathology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Endoscopy & GI Diagnostic Centers (HLAFAKAG)

akta.pro secondary industries

Colorectal Disease & Proctology (HLAKAEAJ), Gastrointestinal Oncology (HLAKAFAK), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Outpatient Endoscopy & GI Procedure Centers (Non-ASC) (HLAFABAL)

Keywords

• Gastrointestinal pathology services
• Surgical pathology laboratory
• GI diagnostic testing
• Digital pathology solutions
• Barrett's esophagus testing

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Pathology Diagnostic Services: Laboratory diagnostic testing services for gastrointestinal specimens, including tissue analysis, pathology reports, and specialized GI testing. Revenue generated through billable pathology services to healthcare providers and insurance companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Vizia Diagnostics operates a state-of-the-art surgical pathology laboratory exclusively specializing in gastrointestinal pathology diagnosis. The company utilizes GI subspecialty-trained pathologists and histotechnicians to provide diagnostic services on GI specimens, with electronic results interface to provider EHR systems and 24/7 access to reports via the PathView portal. Additionally, Vizia facilitates AI-driven precision medicine tests such as TissueCypher for Barrett's esophagus risk assessment.

Product overview

Vizia Diagnostics operates as a state-of-the-art surgical pathology laboratory specializing in gastrointestinal (GI) diagnostics. The core offering is GI pathology services utilizing GI-trained pathologists and histotechnicians. The product portfolio includes PathView (real-time provider report portal), giComply (electronic requisition system), patient and provider billing portals, and the TissueCypher Barrett's Esophagus test (facilitated AI-driven risk assessment). A patient Resource Center provides educational materials on GI conditions.

Differentiator

Problem solved

Functional benefit

Brands

• PathView: Provider portal for real-time 24/7 access to GI pathology reports
• giComply

Products and services

• Gastrointestinal (GI) Pathology Services Surgical pathology laboratory services specializing in gastrointestinal diagnostics for gastroenterologists and ambulatory surgery centers, utilizing GI-trained pathologists and histotechnicians. Provides diagnostic patient care for GI specimens with real-time electronic results delivery to provider EHR systems.
• PathView Provider Portal Direct report portal providing real-time 24/7 access to GI pathology reports for healthcare providers.
• giComply Electronic Requisitions Electronic requisitions system intended to eliminate the need for paper requisitions, jar labels, and patient logs in pathology ordering.
• Provider Billing Portal (XIFIN) Billing management portal for existing provider clients to manage patient billing through XIFIN.
• TissueCypher Barrett's Esophagus Test AI-driven precision medicine test facilitated by Vizia for Castle Biosciences, providing personalized 5-year cancer risk predictions and risk classification (low/intermediate/high) for Barrett's esophagus patients.

Quantifiable outcome

• Adenoma Detection Rate (ADR) tracking through quarterly reports
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Castle Biosciences (TissueCypher)coreStrategic or Co-development Partner · 16 January 2025VIZIA Diagnostics facilitates orders for the TissueCypher Barrett's Esophagus test, an AI-driven precision medicine test that provides personalized cancer risk predictions by analyzing cellular, molecular, and morphologic information from tissue biopsies. The test delivers 5-year probability of progression to high-grade dysplasia or esophageal cancer for Barrett's esophagus patients.
• PathAIcoreTechnology or Integration · 31 October 2024VIZIA Diagnostics adopted PathAI's AISight Image Management System (IMS) and AI technology to advance precision and operational efficiency of pathology services. AISight provides cloud-native workflow optimization, advanced case management, and integration of AI tools for improved turnaround times and higher-quality pathology services.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Inform Diagnostics: A specialty anatomic pathology laboratory (formerly Miraca Life Sciences GI division) with a strong GI subspecialty focus. Directly competes with Vizia for gastroenterologist and ASC pathology referrals with a similar subspecialty-trained model.
• Poplar Healthcare: Regional anatomic pathology lab serving GI and women's health practices across the Southeast U.S. Competes with Vizia for the same gastroenterology and ASC customer base in overlapping geographies.
• AmeriPath (Sonic Healthcare USA): Sonic Healthcare's U.S. anatomic pathology subsidiary offering GI and multi-specialty pathology services to physicians, hospitals, and surgery centers. Competes with Vizia for GI practice and ASC referrals at greater scale.
• GI Pathology (GI Pathology Associates / GI Pathology, PLLC): Independent gastrointestinal pathology laboratory offering subspecialty GI diagnostic services to gastroenterology practices and ASCs. A direct niche peer competing for the same GI referral market.
• ProPath: Independent subspecialty anatomic pathology lab with strong GI, dermatopathology, and other specialty offerings. Closely mirrors Vizia's subspecialty-focused service model and customer base.

Broad incumbents

• Laboratory Corporation of America (LabCorp): National diagnostic lab with significant anatomic pathology capacity including GI specimens. Competes with Vizia through scale, integrated clinical pathology offerings, and national contracts with health systems.
• ARUP Laboratories: Academic-affiliated national reference laboratory offering specialized anatomic and clinical pathology including GI subspecialty diagnostics. Competes with Vizia for complex GI cases and academic GI practices.
• Quest Diagnostics: National clinical and anatomic pathology giant offering GI pathology among a broad test menu. Competes on price, payer contracts, and one-stop-shop convenience to multi-specialty practices.

Others

• PathAI: AI digital pathology platform provider whose AISight system Vizia uses. While not a lab, PathAI's direct AI tools could eventually be sold into GI practices, representing both a partnership upside and a channel risk.

Emerging players

• Castle Biosciences: AI-driven precision medicine company behind the TissueCypher Barrett's Esophagus test. While a partner of Vizia, it represents a potential channel conflict and adjacent competitor in GI molecular diagnostics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/viziadx
• Facebookfacebook.com/viziadx
• Instagraminstagram.com/viziadx
• LinkedInlinkedin.com/company/vizia-diagnostics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vizia Diagnostics